The reduction of EAAT2 expression is associated with several neurological disorders, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), Parkinson’s disease (PD), schizophrenia, and epilepsy [35]. Here, SLC1A2 is linked to Alzheimer disease.